USTR Opens Section 301 Probe Into German Drug Pricing

Posted 6/19/26

The Section 301 investigation turns a drug-pricing dispute into a trade fight, testing whether the Trump administration can use tariff law to pressure Germany and other wealthy markets to pay more for patented medicines. The case signals a broader effort to make foreign pharmaceutical reimbursement policy part of U.S. trade enforcement.

This item is available in full to subscribers.

Please log in to continue

Log in